Pancreatic Cancer Research

ResearcherUniversity of SurreyActive in the last 2 years

Nicola E. Annels

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6795-5616; OpenAlex author ID A5003039959. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers · 2025: none · 2026: 1 paper

Papers 9

  1. Coordinated immune architecture underlies durable survival in pancreatic cancer Co-author DOI 10.64898/2026.04.29.721612↗
  2. Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2024.04.009↗
  3. Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma? Co-author DOI 10.1080/17474124.2024.2363222↗
  4. Implications of the microbiome after pancreatic cancer resection with regard to morbidity and mortality. Co-author DOI 10.1080/17474124.2024.2427648↗
  5. The microbial composition of pancreatic ductal adenocarcinoma: a systematic review of 16S rRNA gene sequencing. Co-author DOI 10.1097/js9.0000000000001762↗
  6. Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15174265↗
  7. Bile Microbiome Signatures Associated with Pancreatic Ductal Adenocarcinoma Compared to Benign Disease: A UK Pilot Study. Co-author DOI 10.3390/ijms242316888↗
  8. A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14041020↗
  9. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patie… Co-author DOI 10.1007/s00262-013-1502-y↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adam Enver Frampton · 8 shared papers, 2022–2026 · strength 1.55
  2. Nabeel Merali · 7 shared papers, 2022–2026 · strength 1.29
  3. Tarak Agrebi Moumni Chouari · 7 shared papers, 2022–2026 · strength 1.29
  4. Shivan Sivakumar · 5 shared papers, 2023–2026 · strength 0.92
  5. Elisa Giovannetti · 5 shared papers, 2022–2026 · strength 0.90
  6. Keith John Roberts · 2 shared papers, 2023–2024 · strength 0.31
  7. Eirini G. Velliou · 2 shared papers, 2023–2024 · strength 0.31
  8. Jonathan Krell · 2 shared papers, 2022–2023 · strength 0.28
  9. Lucy J. A. Harriss · 1 shared paper, 2024 · strength 0.26
  10. Lewis G. Stevens · 1 shared paper, 2024 · strength 0.26
  11. Anguraj Sadanandam · 1 shared paper, 2026 · strength 0.21
  12. Rachael J. M. Bashford-Rogers · 1 shared paper, 2026 · strength 0.21
  13. Michael Loran Dustin · 1 shared paper, 2026 · strength 0.21
  14. Shihong Wu · 1 shared paper, 2026 · strength 0.21
  15. Alex Nicolas Gordon-Weeks · 1 shared paper, 2026 · strength 0.21
  16. Daniel Osei‐Bordom · 1 shared paper, 2024 · strength 0.19
  17. James Michael Halle-Smith · 1 shared paper, 2024 · strength 0.17
  18. Dongmei Deng · 1 shared paper, 2024 · strength 0.17
  19. Daniel Liu · 1 shared paper, 2023 · strength 0.14
  20. Gary Middleton · 1 shared paper, 2014 · strength 0.04
  21. Victoria E. Shaw · 1 shared paper, 2014 · strength 0.04
  22. John P. Neoptolemos · 1 shared paper, 2014 · strength 0.04
  23. David Cunningham · 1 shared paper, 2014 · strength 0.04
  24. Juan W. Valle · 1 shared paper, 2014 · strength 0.04
  25. Pippa G. Corrie · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.